Alecensa (alectinib capsules – Genentech) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has anaplastic lymphoma kinase (ALK)-positive disease
• Patient meets ONE of the following: medication is used for palliative-intent therapy OR patient has relapsed or refractory disease

Approval duration

1 year